Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early diastolic strain rate in relation to long term prognosis following isolated coronary artery bypass grafting

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of peripheral artery disease on major adverse cardiovascular events following myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment of cardiac arrhythmias using long-term continuous monitoring in patients with pulmonary hypertension

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prolonged QT-interval in cirrhosis: is it reversible?

    Research output: Contribution to journalEditorialResearchpeer-review

  5. Electrocardiographic T-wave morphology and risk of mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: To compare effectiveness and safety of clopidogrel, prasugrel, and ticagrelor among all-comers with ST-segment elevation myocardial infarction (STEMI) and extend the knowledge from randomized clinical trials.

METHODS: All consecutive patients with STEMI admitted to Copenhagen University Hospital, Rigshospitalet, from 2009 to 2016 were identified via the Eastern Danish Heart Registry. By individual linkage to Danish nationwide registries, claimed drugs and end points were obtained. Patients alive a week post-discharge were included, stratified according to clopidogrel, prasugrel, or ticagrelor treatment, and followed for a year. The effectiveness end point (a composite of all-cause mortality, recurrent myocardial infarction, and ischemic stroke) and safety end point (a composite of bleedings leading to hospitalization) were assessed by multivariate Cox proportional-hazards models.

RESULTS: In total, 5123 patients were included (clopidogrel [1245], prasugrel [1902], ticagrelor [1976]) with ≥95% treatment persistency. Concomitant use of aspirin was ≥95%. Females accounted for 24% and elderly for 17%. Compared with clopidogrel, the effectiveness end point occurred less often for ticagrelor (HR 0.50, 95% CI 0.35-0.70) and prasugrel (HR 0.48, 95% CI 0.33-0.68) without differences in bleedings leading to hospitalization. No differences in comparative effectiveness or safety were found between prasugrel and ticagrelor. Sensitivity analyses with time-dependent drug exposure and the period 2011-2015 showed similar results.

CONCLUSIONS: Among all-comers with STEMI, ticagrelor and prasugrel were associated with reduced incidence of the composite end point of all-cause mortality, recurrent myocardial infarction, and ischemic stroke without an increase in bleedings leading to hospitalization compared with clopidogrel. No differences were found between prasugrel and ticagrelor.

Original languageEnglish
JournalInternational Journal of Cardiology
Volume342
Pages (from-to)15-22
Number of pages8
ISSN0167-5273
DOIs
Publication statusPublished - 1 Nov 2021

Bibliographical note

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

    Research areas

  • Clopidogrel, Prasugrel, ST-segment elevation myocardial infarction, Ticagrelor

ID: 67986679